Slingshot members are tracking this event:
Post hoc subgroup analyses released of the Phase 3 MACE and SUSTAIN 6 studies evaluating Novo Nordisk's (NVO) OZEMPIC (semaglutide) in type 2 diabetics with high CV risk
- Source Link:
Do you think this event is important to the companies below? How will it affect their stock price?
|Impact on Stocks
Slingshot Insights Explained
Aug 26, 2018
Don’t see a project related to the catalyst you care about?
Related Keywords Phase 3 Study, Mace, Sustain 6 Trial, Ozempic, Semaglutide, Diabetes